ArticleBiochemical genetics2026
POLR2H Serves as a Novel Prognostic Biomarker Correlated with Immune Infiltration in Prostate Cancer.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prostate cancer is a prevalent malignancy, and effective biomarkers are needed to improve patient management. This study aimed to explore the prognostic value and potential functions of POLR2H in prostate cancer. Prognosis-related genes for prostate cancer were screened through high-throughput functional screening using CRISPR. qPCR was used to detect POLR2H expression in different prostate cancer cell lines, prostate hyperplasia cell lines, and normal human prostate epithelial cells. Transwell and scratch assays were conducted to assess cell migration ability. Cell proliferation ability was evaluated by CCK-8 and colony formation assays. POLR2H emerged as a gene of interest associated with patient outcomes. Its expression was found to be elevated in prostate cancer cell lines compared with benign and normal prostate cells. Functional assays indicated that altering POLR2H levels affected cell migration and proliferation. Moreover, analysis across patient cohorts suggested an association between POLR2H expression and immune cell infiltration, implying a potential role in immunotherapy response. These findings support the role of POLR2H as a promising prognostic marker and potential therapeutic target in prostate cancer.
Indexed as
Identifiers
40471404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.